Previous close | 36.50 |
Open | 35.66 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 34.53 - 36.51 |
52-week range | 13.89 - 43.04 |
Volume | |
Avg. volume | 681 |
Market cap | 19.545M |
Beta (5Y monthly) | 1.13 |
PE ratio (TTM) | 3.88 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SAN DIEGO, April 29, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences:
SAN DIEGO, April 09, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2024 results after the financial markets close on Thursday, May 2, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2024 financial and operating results.
Chief Operating & Growth Officer Peyton Howell to succeed Jamie Macdonald effective May 15, 2024; Mr. Macdonald to retire as CEO and continue on the Board of Directors through Dec. 31, 2024DURHAM, N.C., March 18, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced that Jamie Macdonald will retire and transition his role as Chief Executive Officer (CEO) to the c